Financial Performance - The company's revenue for Q1 2024 reached ¥931,696,552.76, representing a 12.32% increase compared to ¥829,526,542.00 in the same period last year[5] - Net profit attributable to shareholders increased by 65.43% to ¥82,971,349.76 from ¥50,154,655.33 year-on-year[5] - Basic and diluted earnings per share increased by 69.23% to ¥0.22, compared to ¥0.13 in the same period last year[5] - The net profit for Q1 2024 reached CNY 89,158,928.05, representing a significant increase of 62.5% from CNY 54,879,668.97 in Q1 2023[23] - The company's basic and diluted earnings per share for Q1 2024 were both CNY 0.22, compared to CNY 0.13 in the same period last year, marking a 69.2% increase[24] Cash Flow - The net cash flow from operating activities rose by 54.94% to ¥41,373,196.64, up from ¥26,703,337.29 in the previous year[11] - The net cash flow from operating activities for the current period is ¥41,373,196.64, an increase of 55% compared to ¥26,703,337.29 in the previous period[27] - Total cash inflow from operating activities is ¥908,762,226.03, up from ¥772,155,286.99, reflecting a growth of approximately 17.7%[27] - Cash outflow from operating activities increased to ¥867,389,029.39 from ¥745,451,949.70, representing a rise of about 16.4%[27] - The net cash flow from financing activities decreased by 68.97% to ¥25,751,266.86, down from ¥82,984,423.07 in the previous year, primarily due to stock repurchase expenditures[11] - The net cash flow from financing activities is ¥25,751,266.86, down from ¥82,984,423.07, showing a decrease of approximately 69%[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,900,503,765.77, a slight decrease of 0.26% from ¥5,916,079,328.81 at the end of the previous year[5] - The total liabilities decreased to CNY 2,081,569,716.22 from CNY 2,135,019,888.07, indicating a reduction of 2.5% year-over-year[21] - The company experienced an 86.88% increase in current liabilities due within one year, totaling ¥205,490,777.68, compared to ¥109,957,297.08 in the previous year[9] Research and Development - Research and development expenses increased by 32.32% to ¥37,715,121.84, up from ¥28,502,407.61 in the previous year[10] - Research and development expenses for Q1 2024 were CNY 37,715,121.84, up from CNY 28,502,407.61 in Q1 2023, indicating a 32.3% increase[22] Shareholder Information - The largest shareholder, Zibo Jincheng Industrial Investment Co., holds 20.46% of the shares, amounting to 78,552,154 shares, with 33,556,400 shares pledged[14] - The second-largest shareholder, the National Social Security Fund, holds 2.94% of the shares, totaling 11,300,000 shares[14] - The company’s repurchase account holds 4,543,000 shares, accounting for 1.18% of the total share capital[14] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[14] Inventory and Receivables - Accounts receivable decreased to ¥560,843,824.49 from ¥608,006,392.29, indicating a reduction of about 7.8%[19] - Inventory increased to ¥533,067,145.66 from ¥501,281,573.25, representing a rise of approximately 6.3%[19] Financial Assets - The company’s financial assets include derivative financial assets valued at ¥223,563.77, a significant increase from ¥20,507.24[19] - The company’s prepayments increased to ¥35,633,225.09 from ¥30,701,553.69, reflecting a growth of approximately 16.0%[19] Overall Financial Health - The weighted average return on equity improved to 2.22%, up from 1.38% in the previous year[5] - The total equity attributable to shareholders of the parent company increased to CNY 3,744,616,592.63 from CNY 3,714,133,643.74, reflecting a growth of 0.8%[21] - The company reported a significant increase in contract liabilities by 41.87% to ¥46,446,623.27, compared to ¥32,738,866.37 in the previous year[9]

2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300233 证券简称：金城医药 公告编号：2024-044 山东金城医药集团股份有限公司 通过现场和网络投票的股东 22 人，代表股份 90,628,504 股，占上市公司有 表决权股份总数的 23.8916％。 其中：通过现场投票的股东 7 人，代表股份 87,360,554 股，占上市公司有表 决权股份总数的 23.0301％。 通过网络投票的股东 15 人，代表股份 3,267,950 股，占上市公司有表决权股 份总数的 0.8615％。 特别提示： 1、本次股东大会不存在增加、变更、否决议案的情况； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开情况 本次会议的召集、召开符合《中华人民共和国公司法》《上市公司股东大会 规则》《深圳证券交易所创业板股票上市规则》等有关法律、行政法规、部门规 章、规范性文件和《山东金城医药集团股份有限公司章程》的有关规定。 二、会议出席情况 （一）股东总体出席情况 1、召开时间：2024 年 4 月 19 日（ ...

北京市中伦（青岛）律师事务所 关于山东金城医药集团股份有限公司 2023 年年度股东大会的 法律意见书 二〇二四年四月 北京市中伦（青岛）律师事务所 关于山东金城医药集团股份有限公司 2023 年年度股东大会的 法律意见书 致：山东金城医药集团股份有限公司 北京市中伦（青岛）律师事务所（以下简称"本所"）接受山东金城医药集 团股份有限公司（以下简称"公司"）的委托，根据本法律意见书出具日前已经 发生或存在的事实和《中华人民共和国公司法》（以下简称《公司法》）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》《律师事 务所从事证券法律业务管理办法》《律师事务所证券法律业务执业规则（试行）》 等中华人民共和国（以下简称"中国"，为本法律意见书之目的，不包括香港特 别行政区、澳门特别行政区和台湾地区）现行有效的法律、法规和规范性文件以 及《山东金城医药集团股份有限公司章程》（以下简称"《公司章程》"）、《山东金 城医药集团股份有限公司股东大会议事规则》（以下简称"《股东大会议事规则》"） 等有关规定，指派律师出席公司于 2024 年 4 月 19 日召开的 2023 年年度股东大 会（ ...

山东金城医药集团股份有限公司之全资子公司山东金城昆仑药业有限公司 于近日收到国家药品监督管理局下发的化学原料药上市批准通知书（通知书编 号：2024YS00257）。现将相关情况公告如下： 一、药品的基本情况 化学原料药名称：乳糖酸克拉霉素 包装规格：20kg/桶 化学原料药注册标准编号：YBY62642024 生产企业：山东金城昆仑药业有限公司 证券代码：300233 证券简称：金城医药 公告编号：2024-043 山东金城医药集团股份有限公司 关于子公司收到化学原料药上市批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 本次乳糖酸克拉霉素获得《化学原料药上市批准通知书》，表明该原料药已 符合国家相关原料药审评技术标准，在符合药品生产质量管理规范要求后，可在 国内市场进行生产销售，将进一步丰富公司的产品线，有利于提升公司在化学原 料药领域的市场竞争力。药品的销售可能受到国家政策、市场环境变化等综合因 素影响，存在不确定性。敬请广大投资者注意风险，理性投资。 特此公告。 山东金城医药集团股份有限公司董事会 申请事项：境内生产化学原料药上市申请 ...

证券代码：300233 证券简称：金城医药 公告编号：2024-042 山东金城医药集团股份有限公司 关于举行 2023 年度网上业绩说明会的公告 会议召开方式：网络文字互动方式 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）已于 2024 年 3 月 29 日在巨 潮资讯网上披露了《2023 年年度报告》及《2023 年年度报告摘要》。为便于广大投资 者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2024 年 4 月 9 日（星 期二）15:00-17:00 在"价值在线"（www.ir-online.cn）举行山东金城医药集团股份 有限公司 2023 年度业绩说明会，与投资者进行沟通和交流，广泛听取投资者的意见和 建议。 一、会议召开的时间、地点和方式 会议召开时间：2024 年 4 月 9 日（星期二）15:00-17:00 会议召开地点：价值在线（www.ir-online.cn） 三、投资者参加方式 投资者可于2024年4月9日（星期二）15:00-17:00通过网址https://es ...

Financial Performance - In 2023, the company's operating revenue reached ¥3,538,312,459.65, a slight increase of 0.93% compared to ¥3,505,716,962.18 in 2022[47]. - The net profit attributable to shareholders was ¥174,709,358.21, representing a decrease of 36.09% from ¥273,364,594.00 in 2022[47]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥158,182,714.58, down 40.12% from ¥264,176,652.65 in 2022[47]. - The net cash flow from operating activities significantly increased by 159.78% to ¥664,075,132.81 from ¥255,626,529.37 in 2022[47]. - The total assets at the end of 2023 amounted to ¥5,916,079,328.81, reflecting a 1.54% increase from ¥5,826,083,590.97 in 2022[47]. - The net assets attributable to shareholders increased by 2.96% to ¥3,714,133,643.74 from ¥3,607,438,065.73 in 2022[47]. - The basic earnings per share decreased by 36.62% to ¥0.45 from ¥0.71 in 2022[47]. - The diluted earnings per share also decreased by 36.62% to ¥0.45 from ¥0.71 in 2022[47]. - The weighted average return on net assets was 4.75%, down from 7.81% in 2022, a decrease of 3.06%[47]. - The company reported a total of ¥20,542,633.74 in government subsidies, an increase from ¥19,141,348.49 in 2022[47]. Innovation and R&D - The company has applied for several patents during the reporting period, indicating ongoing innovation efforts[2]. - The company is focusing on R&D with several patents filed in 2023, indicating a commitment to innovation and market expansion[89]. - The company has established research institutes to accelerate the development of terminal formulations, specialty raw materials, and high-end pharmaceutical intermediates[97]. - The company emphasizes a three-tiered R&D innovation system that integrates independent innovation, collaborative innovation, and investment innovation[97]. - The company is actively pursuing international certification for several products, including new drugs like chlorpheniramine and oseltamivir phosphate[63]. - The company is exploring new technologies and methods to enhance production efficiency and product quality, as shown by its recent patent filings[89]. Market Strategy and Expansion - The company focuses on four strategic development directions: Pharma-Chem, synthetic biology, Fem-Tech, and high-quality antibiotics, enhancing synergy across technology, market, operations, and management[59]. - The company aims to create a well-known brand in women's health technology, with key products including vaginal soft capsules and creams[63]. - The company is actively pursuing new strategies for market expansion and product development, as evidenced by its recent patent applications[89]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share within the next two years[155]. - A strategic acquisition of a local pharmaceutical company is in progress, which is expected to enhance the company's product portfolio and increase market competitiveness[155]. Environmental Compliance and Sustainability - The company has invested over CNY 190 million in environmental protection facilities and operations in 2023, with an environmental protection tax payment of CNY 166,700[168]. - The company reported a nitrogen oxide emission level of 5.33 mg/m³, which is below the standard limit of 10 mg/m³[136]. - The company achieved a COD discharge level of 80.3 mg/L, significantly lower than the B-level standard limit of 500 mg/L[136]. - The company has implemented a new wastewater discharge system that complies with the GB/T 31962-2015 standard[136]. - The company has a comprehensive environmental information disclosure system, including public display boards and online monitoring connections with local environmental authorities[198]. - The company is committed to sustainability, with plans to reduce carbon emissions by 20% over the next five years through various initiatives[155]. Corporate Governance - The company has established a governance structure to protect the rights of shareholders and creditors, ensuring effective checks and balances among the shareholders' meeting, board of directors, and management[199]. - The company’s financial report has been confirmed by its board members, ensuring the accuracy and completeness of the information presented[18]. - The company emphasizes the importance of risk awareness regarding future development statements, highlighting potential policy and market risks[7]. Production and Operations - The company has established nine production bases across multiple provinces, with a strong market share in cephalosporin intermediates and glutathione raw materials[114]. - The company has a production capacity ranging from milligram to ton levels, with total reaction volumes reaching up to 5000 cubic meters for both chemical synthesis and biological fermentation[117]. - The company has integrated automation and intelligent upgrades in production processes to enhance safety and efficiency[118]. - The company adheres to GMP standards in its production processes, ensuring compliance with annual operational goals and market demands[64].

山东金城医药集团股份有限公司 审计报告 上会师报字(2024)第 1265 号 上会会计师事务所（特殊普通合伙） 中国 上海 会计师事务所(特殊普通合伙) rtilied Public Socountants (Special Seneral Par 审计报告 上会师报字(2024)第 1265 号 山东金城医药集团股份有限公司全体股东: 一、审计意见 我们审计了山东金城医药集团股份有限公司(以下简称"贵公司")财务报表, 包括 2023年 12月 31 日的合并及母公司资产负债表,2023年度的合并及母公司利润 表、合并及母公司现金流量表、合并及母公司所有者权益变动表以及相关财务报表 附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公 允反映了贵公司 2023 年 12 月 31 日的合并及母公司财务状况以及 2023 年度的合并及 母公司经营成果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册 会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照 中国注册会计师职业道德守则,我们独立于贵公司,并履行了职 ...

证券代码：300233 证券简称：金城医药 公告编号：2024-034 山东金城医药集团股份有限公司 关于使用闲置自有资金购买理财产品的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）第六届董事会第八次 会议及第六届监事会第六次会议审议通过了《关于使用闲置自有资金购买理财产 品的议案》。为提高资金使用效率，合理利用自有资金，在保证日常经营资金需 求和资金安全的前提下，公司及所属子公司拟使用暂时闲置的自有资金向银行等 金融机构申请购买总额不超过人民币 3 亿元的各类较低风险等级、流动性强的理 财产品，不包括股票、期货、期权、外汇衍生品以及其他金融衍生品等。在此额 度内资金可滚动使用，且公司及子公司在任一时点购买理财产品最高余额不超过 3 亿元人民币。 一、投资概况 1、投资目的：为提高资金使用效率，合理利用闲置自有资金，在不影响公 司正常经营业务的前提下，利用闲置自有资金购买理财产品，增加公司收益。 2、投资额度：拟使用不超过人民币 3 亿元的闲置自有资金购买低风险等级、 流动性强的理财产品，在上述额度内，资 ...

证券代码：300233 证券简称：金城医药 公告编号：2024-039 山东金城医药集团股份有限公司 关于修订《重大交易决策制度》《关联交易决策制度》 的公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 | | --- | | 记载、误导性陈述或重大遗漏。 | 山东金城医药集团股份有限公司（以下简称"公司"）于 2024 年 3 月 27 日 召开第六届董事会第八次会议，审议通过了《关于修订<重大交易决策制度><关联 交易决策制度>的议案。会议审议修订了《重大交易决策制度》《关联交易决策制 度》，具体修订内容如下： 1、《重大交易决策制度》 | 修订前 | 修订后 | | --- | --- | | 第一条 为确保山东金城医药集团股份有限 | 第一条 为确保山东金城医药集团股份有限 | | 公司（以下简称"公司"）重大交易决策程序 | 公司（以下简称"公司"）重大交易决策程 | | 规范、有效，依据《中华人民共和国公司法》 | 序规范、有效，依据《中华人民共和国公司 | | （以下简称《公司法》）、《深圳证券交易所 | 法》（以下简称《公司法》）、《深圳证券 | | 创业板上市公司 ...

第一章 总 则 第一条 为规范公司领导人员的产生，优化董事会组成，完善公 司治理结构，根据《中华人民共和国公司法》《上市公司治理准则》 《山东金城医药集团股份有限公司章程》（以下简称《公司章程》） 及其他有关规定，公司特设立董事会提名委员会，并制定本工作细则。 第二条 董事会提名委员会是董事会设立的专门工作机构，主要 负责对公司董事和高级管理人员的人选、选择标准和程序进行研究并 提出建议。 第二章 人员组成 第三条 提名委员会成员由三名董事组成，其中独立董事二名。 第四条 提名委员会委员（以下简称"委员"）由董事长、二分 之一以上独立董事或者全体董事的三分之一以上提名，并由董事会选 举产生。 山东金城医药集团股份有限公司 董事会提名委员会工作细则 山东金城医药集团股份有限公司 董事会提名委员会工作细则 第五条 提名委员会设主任委员（召集人）一名，由独立董事委 员担任，负责主持委员会工作。召集人在委员会内选举，并报请董事 会批准。 第六条 提名委员会任期与董事会任期一致，委员任期届满，连 选可以连任。期间如有委员不再担任公司董事职务，则自动失去委员 资格，并由董事会根据本细则补足委员人数。 第七条 公司人力资源 ...